|1.||Johnson, Charles A: 1 article (07/2015)|
|2.||Hudson, Graham A: 1 article (07/2015)|
|3.||Hardebeck, Laura K E: 1 article (07/2015)|
|4.||Jolley, Elizabeth A: 1 article (07/2015)|
|5.||Ren, Yi: 1 article (07/2015)|
|6.||Thakur, Shreyasi: 1 article (07/2015)|
|7.||Lewis, Michael: 1 article (07/2015)|
|8.||Cattoni, Diego I: 1 article (07/2015)|
|9.||Nöllmann, Marcelo: 1 article (07/2015)|
|10.||Znosko, Brent M: 1 article (07/2015)|
12/01/1989 - "These include: (i) the production of improved topoisomerase inhibitors (by consideration of drug/protein as well as drug/DNA interactions); (ii) the development of reductively-activated chromophores as hypoxia-selective agents; and (iii) the use of DNA-intercalators of known DNA binding orientation as 'carriers' for the delivery of other reactive functionality specifically (sequence-, regio- and site-specifically) to DNA."
06/01/1999 - "A series of cobalt (III) complexes, [Co(Racac)2(L)]+, have been prepared as potential hypoxia-selective prointercalator forms of the ligands L, where L is the cytotoxic DNA mono-intercalating ligands N-[2-[(aminoethyl)amino]ethyl]-phenazine-1-carboxamide and N-[5-[(aminoethyl)amino]pentyl]-phenazine-1-carboxamide or the potentially bis(intercalating) ligand bis[2-(phenazine-1-carboxamido)ethyl]-1,2-diaminoethane. "
07/01/2007 - "In these studies, we focused on investigating the apoptotic effects of intercalating agents on HPV-negative cervical cancer C-33A cells. "
09/01/2010 - "A class of novel carboline intercalators: Their synthesis, in vitro anti-proliferation, in vivo anti-tumor action, and 3D QSAR analysis."
07/01/2007 - "The apoptotic effect of intercalating agents on HPV-negative cervical cancer C-33A cells."
11/01/1985 - "Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors."
09/01/1985 - "[Molecular biology of intercalating agents used in tumor chemotherapy]."
07/20/1993 - "We have examined the activities of two novel aza-anthracene-9,10-diones (aza), 1-aza and 2-aza, in HL-60 human leukemia cell lines containing type II topoisomerases with different sensitivities to inhibition by other intercalating agents. "
01/01/1988 - "These results in very poor risk leukemia suggest a possible synergism in the action of the two intercalating agents and absence of increased cardiotoxicity."
12/01/2008 - "Almost all of these intercalators showed effective cytoxicities against human lung cancer cells and murine leukemia cells. "
06/15/1990 - "The pharmacodynamics of a new series of antitumor DNA intercalators, known as arylmethylaminopropanediols (AMAPs), has been evaluated in vitro against adherent (MCF-7 human breast cancer) and nonadherent (P388 murine leukemia) cell lines. "
01/01/1986 - "Overadditive synergism between the intercalators mitoxantrone and lucanthone in advanced L 12010 and P 388 leukemia."
10/01/1985 - "The biochemical effects of these agents were studied in L1210 leukemia in relation to other clinically used intercalators. "
01/01/1988 - "The biochemical effects of these drugs on L1210 leukemia cells and their interaction with DNA were studied and compared to clinically used intercalators. "
08/01/1985 - "Activity of platinum(II) intercalating agents against murine leukemia L1210."
08/25/1987 - "DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators."
03/28/1979 - "The intercalating agents, adriamycin and ellipticine, were previously found to produce DNA strand breaks associated with DNA-protein crosslinks in mouse leukemia L1210 cells. "
|1.||DNA (Deoxyribonucleic Acid)
|5.||Histone Deacetylase Inhibitors
|6.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|8.||Type II DNA Topoisomerases (Topoisomerase II)
|1.||Drug Therapy (Chemotherapy)